Novartis announced it will seek approval for a fourth indication for its drug Cosentyx, or secukinumab, to treat axial spondyloarthritis. The company will use data from its late-stage PREVENT trial, which met the study's primary endpoint by achieving Assessment in SpondyloArthritis International Society 40% response in patients with non-radiographic axial spondyloarthritis, to support the FDA submission, and has also filed a marketing application with the European Medicines Agency for the approval of Cosentyx for nr-axSpA.
Novartis to seek FDA approval for new Cosentyx indication
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.